Needham & Company LLC Issues Pessimistic Forecast for Bicycle Therapeutics (NASDAQ:BCYC) Stock Price

Bicycle Therapeutics (NASDAQ:BCYC) had its price objective cut by stock analysts at Needham & Company LLC from $24.00 to $15.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price objective points to a potential upside of 229.67% from the company’s previous close.

Several other research analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Truist Financial set a $8.00 target price on Bicycle Therapeutics in a research report on Tuesday. Morgan Stanley reaffirmed a “sell” rating and issued a $13.00 price target on shares of Bicycle Therapeutics in a research note on Tuesday. Finally, Jefferies Financial Group upgraded Bicycle Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Bicycle Therapeutics has an average rating of “Hold” and a consensus price target of $14.50.

Bicycle Therapeutics Trading Down 3.2%

Shares of NASDAQ BCYC opened at $4.55 on Wednesday. The firm has a market capitalization of $315.63 million, a price-to-earnings ratio of -1.44 and a beta of 1.65. Bicycle Therapeutics has a one year low of $4.47 and a one year high of $9.86. The business has a fifty day simple moving average of $5.83 and a 200 day simple moving average of $6.78.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.71. The firm had revenue of $47.96 million for the quarter, compared to the consensus estimate of $7.08 million. Bicycle Therapeutics had a negative net margin of 301.66% and a negative return on equity of 33.21%. On average, research analysts anticipate that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In related news, CFO Alethia Young sold 4,334 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the completion of the sale, the chief financial officer owned 87,081 shares of the company’s stock, valued at $565,155.69. This trade represents a 4.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin Lee sold 10,989 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $6.46, for a total value of $70,988.94. Following the transaction, the chief executive officer directly owned 618,996 shares in the company, valued at approximately $3,998,714.16. This represents a 1.74% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 38,029 shares of company stock valued at $251,966. Insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Flax Pond Capital LLC bought a new stake in shares of Bicycle Therapeutics during the fourth quarter worth $1,229,000. Invesco Ltd. acquired a new stake in Bicycle Therapeutics in the fourth quarter worth about $71,000. State of Tennessee Department of Treasury raised its holdings in Bicycle Therapeutics by 36.4% during the 4th quarter. State of Tennessee Department of Treasury now owns 61,153 shares of the company’s stock worth $433,000 after purchasing an additional 16,311 shares during the last quarter. XTX Topco Ltd lifted its position in Bicycle Therapeutics by 309.3% during the 4th quarter. XTX Topco Ltd now owns 47,674 shares of the company’s stock valued at $338,000 after purchasing an additional 36,026 shares during the period. Finally, Virtus Investment Advisers LLC lifted its position in Bicycle Therapeutics by 172.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 35,709 shares of the company’s stock valued at $253,000 after purchasing an additional 22,615 shares during the period. Institutional investors own 86.15% of the company’s stock.

Key Stories Impacting Bicycle Therapeutics

Here are the key news stories impacting Bicycle Therapeutics this week:

• Positive Sentiment: Oppenheimer cut its price target from $44 to $36 but maintained an “outperform” rating—still implying large upside from current levels. Read More.
• Positive Sentiment: Needham lowered its target from $24 to $15 but kept a “buy” rating, signaling continued analyst conviction despite the reduction. Read More.
• Positive Sentiment: Citizens JMP trimmed its target from $12 to $8 and kept a “market outperform” view, which supports a constructive medium‑term outlook. Read More.
• Neutral Sentiment: Royal Bank of Canada lowered its target from $11 to $7 and set a “sector perform” rating—more neutral guidance relative to prior coverage. Read More.
• Negative Sentiment: Multiple short‑interest notices flagged a “large increase” in short interest for March, although the published figures show zero shares (likely a data/reporting inconsistency). Still, headlines alone can prompt selling or caution among investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.